SS

Srinivasan Sankaranarayanan

Active Director Director DIN 10168303
DIN 10168303 First appointment May 2023 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Srinivasan Sankaranarayanan

Data last updated:

Srinivasan Sankaranarayanan is a Director at Munin Pharmaceuticals Private Limited (since 2023). The company operates in Pharma.

DIN 10168303
Primary Designation Director
Industry Pharma
First Appointment 18 May 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 May 20232023Active

Board colleagues of Srinivasan Sankaranarayanan

NameDINCompanyDesignation
Chandrakala Balakrishnan10168302Munin Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Munin Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Srinivasan Sankaranarayanan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Srinivasan Sankaranarayanan

Srinivasan Sankaranarayanan currently holds 1 directorship: Munin Pharmaceuticals Private Limited (Director, since 18 May 2023).

Srinivasan Sankaranarayanan was first appointed on 18 May 2023 as Director at Munin Pharmaceuticals Private Limited.

The current boards of Srinivasan Sankaranarayanan's companies include Chandrakala Balakrishnan (Munin Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available